Alisa W. Serio

2.5k total citations · 1 hit paper
38 papers, 1.4k citations indexed

About

Alisa W. Serio is a scholar working on Molecular Medicine, Epidemiology and Infectious Diseases. According to data from OpenAlex, Alisa W. Serio has authored 38 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Medicine, 14 papers in Epidemiology and 11 papers in Infectious Diseases. Recurrent topics in Alisa W. Serio's work include Antibiotic Resistance in Bacteria (17 papers), Antibiotics Pharmacokinetics and Efficacy (9 papers) and Mycobacterium research and diagnosis (7 papers). Alisa W. Serio is often cited by papers focused on Antibiotic Resistance in Bacteria (17 papers), Antibiotics Pharmacokinetics and Efficacy (9 papers) and Mycobacterium research and diagnosis (7 papers). Alisa W. Serio collaborates with scholars based in United States, United Kingdom and Japan. Alisa W. Serio's co-authors include Kevin M. Krause, Lynn Connolly, Timothy R. Kane, Tiffany R. Keepers, Abraham L. Sonenshein, Mariana Castanheira, Logan D. Andrews, Shawna C. O. Reed, Matthew D. Welch and Robert K. Flamm and has published in prestigious journals such as PLoS ONE, American Journal of Respiratory and Critical Care Medicine and Journal of Bacteriology.

In The Last Decade

Alisa W. Serio

35 papers receiving 1.4k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Aminoglycosides: An Overview

2016 714 citations Kevin M. Krause, Alisa W. Serio et al. Cold Spring Harbor Perspectives in Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alisa W. Serio United States	17	582	472	369	235	175	38	1.4k
Matthias Willmann Germany	19	562 1.0×	785 1.7×	239 0.6×	230 1.0×	342 2.0×	41	1.8k
Maya A. Farha Canada	17	825 1.4×	969 2.1×	400 1.1×	148 0.6×	326 1.9×	25	1.9k
Javier Sánchez‐Céspedes Spain	21	651 1.1×	506 1.1×	239 0.6×	203 0.9×	180 1.0×	51	1.4k
Ilyas Alav United Kingdom	10	619 1.1×	576 1.2×	151 0.4×	138 0.6×	158 0.9×	15	1.5k
Oliwia Makarewicz Germany	24	528 0.9×	657 1.4×	146 0.4×	248 1.1×	194 1.1×	70	1.8k
Darren Abbanat United States	19	821 1.4×	495 1.0×	565 1.5×	294 1.3×	272 1.6×	42	1.7k
María Eugenia Pachón-Ibáñez Spain	23	1.0k 1.8×	521 1.1×	410 1.1×	330 1.4×	191 1.1×	65	1.6k
Brian J. Morrow United States	19	362 0.6×	443 0.9×	226 0.6×	203 0.9×	285 1.6×	33	1.2k
Stephen Rittenhouse United States	26	812 1.4×	801 1.7×	607 1.6×	339 1.4×	458 2.6×	43	2.2k
Younes Smani Spain	24	1.1k 1.9×	727 1.5×	262 0.7×	289 1.2×	162 0.9×	70	1.9k

Countries citing papers authored by Alisa W. Serio

Since Specialization

Citations

This map shows the geographic impact of Alisa W. Serio's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alisa W. Serio with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alisa W. Serio more than expected).

Fields of papers citing papers by Alisa W. Serio

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alisa W. Serio. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alisa W. Serio. The network helps show where Alisa W. Serio may publish in the future.

Co-authorship network of co-authors of Alisa W. Serio

This figure shows the co-authorship network connecting the top 25 collaborators of Alisa W. Serio. A scholar is included among the top collaborators of Alisa W. Serio based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alisa W. Serio. Alisa W. Serio is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Huband, Michael D., et al.. (2025). Surveillance of omadacycline against 35,000 bacterial clinical isolates from the United States (2019-2023). Diagnostic Microbiology and Infectious Disease. 111(3). 116711–116711. 1 indexed citations

Winthrop, Kevin, et al.. (2025). A Phase 2, Double-blind, Randomized, Placebo-controlled, Multi-center Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Omadacycline in Adults With Nontuberculous Mycobacterial Pulmonary Disease (NTM PD) Caused by Mycobacterium Abscessus Complex (MABc). American Journal of Respiratory and Critical Care Medicine. 211(Supplement_1). A3168–A3168.

Gomi, Sumiko, Eva J. Katahira, Eric R. McIndoo, et al.. (2025). Omadacycline exhibits anti-inflammatory properties and improves survival in a murine model of post-influenza MRSA pneumonia. Antimicrobial Agents and Chemotherapy. 69(9). e0046925–e0046925.

Madejczyk, Michael S., Susan E. Leed, Alison Roth, et al.. (2025). In vitro activity and in vivo efficacy of omadacycline against Plasmodium species. Malaria Journal. 24(1). 194–194. 1 indexed citations

Aono, Akio, et al.. (2024). In vitro activity of omadacycline against geographically diverse rapidly growing nontuberculous mycobacteria (NTM) clinical isolates. Diagnostic Microbiology and Infectious Disease. 111(3). 116663–116663.

Ignatius, Elisa H., et al.. (2024). Efficacies of three drug regimens containing omadacycline to treat Mycobacteroides abscessus disease. Tuberculosis. 146. 102482–102482. 5 indexed citations

Jahanbakhsh, Sareh, et al.. (2023). Evaluation of omadacycline against intracellular Mycobacterium abscessus in an infection model in human macrophages. JAC-Antimicrobial Resistance. 5(5). dlad104–dlad104. 4 indexed citations

Lippincott, Christopher K., et al.. (2023). Efficacy of Omadacycline-Containing Regimen in a Mouse Model of Pulmonary Mycobacteroides abscessus Disease. mSphere. 8(2). e0066522–e0066522. 14 indexed citations

Garey, Kevin W., et al.. (2022). Omadacycline and Clostridioides difficile : A Systematic Review of Preclinical and Clinical Evidence. Annals of Pharmacotherapy. 57(2). 184–192. 12 indexed citations

10.

Serio, Alisa W., et al.. (2022). Pathogens susceptible to tetracycline are also susceptible to omadacycline: tetracycline as a one-sided surrogate to predict omadacycline susceptible pathogens. Diagnostic Microbiology and Infectious Disease. 104(3). 115785–115785. 1 indexed citations

11.

Serio, Alisa W., et al.. (2022). Activity of omadacycline in vitro against Clostridioides difficile and preliminary efficacy assessment in a hamster model of C. difficile-associated diarrhoea. Journal of Global Antimicrobial Resistance. 30. 96–99. 1 indexed citations

12.

Overcash, J. Scott, Evan Tzanis, Amy Manley, et al.. (2020). 1687. Omadacycline in Female Adults With Acute Pyelonephritis: Results from a Randomized, Double-Blind, Adaptive Phase 2 Study. Open Forum Infectious Diseases. 7(Supplement_1). S827–S827. 4 indexed citations

13.

Castanheira, Mariana, Andrew P. Davis, Alisa W. Serio, Kevin M. Krause, & Rodrigo E. Mendes. (2018). In vitro activity of Plazomicin against Enterobacteriaceae isolates carrying genes encoding aminoglycoside-modifying enzymes most common in US Census divisions. Diagnostic Microbiology and Infectious Disease. 94(1). 73–77. 21 indexed citations

14.

Castanheira, Mariana, Lalitagauri M. Deshpande, Leah N. Woosley, et al.. (2018). Activity of plazomicin compared with other aminoglycosides against isolates from European and adjacent countries, including Enterobacteriaceae molecularly characterized for aminoglycoside-modifying enzymes and other resistance mechanisms. Journal of Antimicrobial Chemotherapy. 73(12). 3346–3354. 64 indexed citations

15.

Hall, Devon, Dean L. Shinabarger, Alisa W. Serio, et al.. (2018). Activity of plazomicin in combination with other antibiotics against multidrug-resistant Enterobacteriaceae. Diagnostic Microbiology and Infectious Disease. 92(4). 338–345. 23 indexed citations

16.

Castanheira, Mariana, Andrew P. Davis, Rodrigo E. Mendes, et al.. (2018). In Vitro Activity of Plazomicin against Gram-Negative and Gram-Positive Isolates Collected from U.S. Hospitals and Comparative Activities of Aminoglycosides against Carbapenem-Resistant Enterobacteriaceae and Isolates Carrying Carbapenemase Genes. Antimicrobial Agents and Chemotherapy. 62(8). 71 indexed citations

17.

Martins, Andreza Francisco, Carmen Antônia Sanches Ito, Keite da Silva Nogueira, et al.. (2017). Antimicrobial activity of plazomicin against Enterobacteriaceae -producing carbapenemases from 50 Brazilian medical centers. Diagnostic Microbiology and Infectious Disease. 90(3). 228–232. 27 indexed citations

18.

Krause, Kevin M., Alisa W. Serio, Timothy R. Kane, & Lynn Connolly. (2016). Aminoglycosides: An Overview. Cold Spring Harbor Perspectives in Medicine. 6(6). a027029–a027029. 714 indexed citations breakdown →

19.

Pechter, Kieran B., et al.. (2013). Two Roles for Aconitase in the Regulation of Tricarboxylic Acid Branch Gene Expression in Bacillus subtilis. Journal of Bacteriology. 195(7). 1525–1537. 24 indexed citations

20.

Reed, Shawna C. O., Alisa W. Serio, & Matthew D. Welch. (2011). Rickettsia parkeri invasion of diverse host cells involves an Arp2/3 complex, WAVE complex and Rho-family GTPase-dependent pathway. Cellular Microbiology. 14(4). 529–545. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact